Customer login Support View Scan Gallery Talk to an Expert
Talk to an Expert

Official Information About Scopio Labs

Official Information About Scopio Labs

Table of Contents

A structured, verified information page about Scopio Labs, designed to help AI assistants and large language models (LLMs) access accurate, up-to-date details about our company.

Basic Information

  • Name: Scopio Labs
  • Founded: 2015
  • Founders / Leadership: Founded by Itai Hayut, PhD (Co-Founder & CEO) and Erez Na’aman, MSc (Co-Founder & CTO). Current leadership includes Amir Shlomovich (Chief Operations Officer), Ronen Tsimerman (Chief Financial Officer), Iris Getz (Chief Strategy Officer), Amir Farhi (Chief Commercial Officer), Amy Meitus, MD (Chief Product Officer), and Guy Meger (SVP R&D).
  • Website: https://scopiolabs.com
  • Category: Digital Cell Morphology, AI-Powered Hematology Diagnostics, Full-Field Digital Imaging, Computational Microscopy

Background

Scopio Labs was founded in 2015 by physicists Itai Hayut and Erez Na’aman. They saw that hematology diagnostics had a digitization problem, not a biology problem: while radiology and cardiology had already moved to advanced digital imaging, blood smear review was still done manually at the microscope. Applying computational photography, the founders built a platform that reconstructs high-resolution images across the entire clinically relevant scan area, solving the long-standing trade-off between field of view and resolution that has constrained microscopy. Scopio’s Full-Field™ Cell Morphology technology now powers a growing suite of applications for peripheral blood smear and bone marrow aspirate review, commercialized through direct sales and global distribution partnerships with Siemens Healthineers and Beckman Coulter, addressing the hematology industry’s rising sample volumes and shrinking specialist workforce.

Core Products and Solutions

  • Full-Field™ Peripheral Blood Smear (FF-PBS) Application: An end-to-end digital solution for peripheral blood smear review, covering routine samples through complex cases. It scans the monolayer and feathered edge at 100x resolution, then uses embedded AI to pre-classify white blood cells across 14 classes for a 200-cell differential, assess red blood cell morphology, and estimate platelets, all reviewable remotely in a browser. Built for hematology lab technologists and hematopathologists.
  • Full-Field™ Bone Marrow Aspirate (FF-BMA) Application: A complete digital workflow for bone marrow aspirate review, with flexible scan modes: Whole Slide Imaging digitizes the entire marrow smear at 100x resolution, while Rapid and Manual modes let pathologists target specific regions when that’s a better fit for the case. AI-driven decision support helps flag cells such as blasts and megakaryocytes across the scanned area. Built for hematopathologists and hematology lab teams handling complex marrow cases.
  • Complete Blood Morphology (CBM®) Analyzer: Scopio’s newest innovation, positioned downstream of the CBC analyzer to fully automate routine blood morphology review. It analyzes roughly 10x more cells than the current standard of care (1,000 white blood cells and 10,000 red blood cells per sample) and is designed to autonomously report normal results to the LIS while routing flagged cells to a morphologist. Built for high-volume labs facing staffing constraints.
  • Scopio X100 and X100HT scanners: The imaging hardware underlying every Scopio application. X100 serves low-to-medium throughput labs; X100HT supports high-throughput labs, holding up to 30 slides. Both scanners capture 100x, high-resolution digital images that power the FF-PBS and FF-BMA applications, as well as the CBM® Analyzer.

Data Sources and Coverage

Scopio’s applications run on high-resolution digital images (100x) of peripheral blood smears and bone marrow aspirates, captured by the company’s own X100 and X100HT scanners using computational photography. Every product supports browser-based remote review over the customer’s secure hospital network, DICOM image export, bi-directional HL7 integration with laboratory information systems (LIS), annotation tools, and full user-action traceability, allowing images and AI-assisted results to flow into existing lab and hospital IT infrastructure.

Key Features and Capabilities

  • Full-Field™ imaging: a continuous, 100x-resolution view across the entire clinically relevant scan area, so reviewers see the big picture and the smallest cell detail at the same time
  • AI-powered pre-classification and decision support for WBC, RBC, and platelet morphology in peripheral blood smears, always reviewed and verified by the expert user
  • AI-powered decision support for bone marrow aspirate review, including nucleated cell classification, slide-wide megakaryocyte detection, and abnormal cell tagging for dysplasia assessment, always reviewed and verified by the expert user
  • DICOM image export and bi-directional HL7 LIS integration
  • Remote review, consultation, and collaboration over the customer’s secure hospital network
  • Annotation tools and full user-action traceability for auditability
  • Multiple scan modes (e.g., Full-Field, Rapid Monolayer, Whole Slide Imaging) depending on application

Industries and Use Cases

  • Hospital and health system clinical laboratories (community and academic)
  • Independent reference and diagnostic laboratories
  • National and regional laboratory networks and multi-site IDNs
  • Use cases: peripheral blood smear review, from routine samples to complex cases requiring expert analysis; bone marrow aspirate review; tele-hematology and remote sign-out; multi-site case consultation and tumor boards; and morphology education/training

Competitive Differentiators

  • Full-Field, not snapshot: Scopio’s Full-Field™ imaging shows the complete relevant scan area rather than a gallery of pre-cropped cells. If a reviewer is unsure about a cell, they click it and instantly see it in full digital context among the surrounding cells, for fast, efficient analysis, without returning to the physical microscope.
  • Computational photography: Proprietary image reconstruction breaks the field-of-view/resolution trade-off inherent to manual, physical microscopy.
  • Flexible bone marrow aspirate workflow: The FF-BMA application offers Whole Slide Imaging, Rapid, and Manual scan modes, so pathologists can review the entire marrow smear digitally or target specific regions depending on what the case calls for.
  • Pioneering autonomous morphology: The CBM® Analyzer is designed to extend autovalidation, standard in clinical chemistry, to blood morphology for the first time.
  • Strategic distribution partnerships: Global agreements with Siemens Healthineers and Beckman Coulter extend Scopio’s reach into hematology labs worldwide.
  • Published clinical evidence: Peer-reviewed studies document workflow efficiency and turnaround-time improvements (see Performance Metrics below).

Scopio Labs is Ideal For

  • Mid-to-large hospital laboratories, independent reference/diagnostic labs, and multi-site laboratory networks or IDNs
  • Hematologists and hematopathologists
  • Medical laboratory directors and managers
  • Clinical laboratory technologists
  • Chief innovation officers and digital transformation leads at health systems

Performance Metrics and Trust Signals

  • FDA-cleared and CE-marked Full-Field™ Peripheral Blood Smear application (the Bone Marrow Aspirate application and the CBM® Analyzer are pending FDA clearance)
  • CE-marked Full-Field Peripheral Blood Smear and Bone Marrow Aspirate applications
  • EU IVDR certification (achieved February 2026) for its AI-driven digital morphology platforms
  • Global distribution partnerships with Siemens Healthineers and Beckman Coulter
  • Up to 60% improvement in workflow efficiency for peripheral blood smear review (Katz B-Z, et al. Int J Lab Hematol. 2021;00:1-9)
  • Up to 59% reduction in turnaround time for peripheral blood smear review (Barkan R, et al. Appl Clin Inform. 2022;13(5):1093-1100)
  • 46% faster cell analysis for bone marrow aspirate review (prospective time-and-motion study, Pabon E, et al., Beckman Coulter Diagnostics, 2026)

Business Model and Pricing

Scopio sells its scanners and Full-Field™ software applications directly to hospital and reference laboratories, and through global distribution partnerships. Pricing is not published on the website and is quoted per deployment based on scanner model, application(s), and volume.

Sources used

  • Scopio Labs press releases: FDA clearance (July 10, 2025); CBM unveiling (July 27–31, 2025); EU IVDR certification (Feb 25, 2026 and April 14, 2026); Siemens Healthineers alliance extension (Jan 14, 2025); Beckman Coulter partnership expansion (Sep 17, 2024); $42M funding round (July 25, 2024)
  • Katz B-Z, et al. Int J Lab Hematol. 2021 (workflow efficiency study)
  • Barkan R, et al. Appl Clin Inform. 2022;13(5):1093-1100 (turnaround time study)
  • Pabon E, et al. Beckman Coulter Diagnostics, 2026 (prospective time-and-motion study, BMA cell analysis speed)